Share this page

 CESTRATA — 1830767

Toolbar

Toolbar

Details

Third-party disclaimer

Share this page

No endorsement of any products or services is expressed or implied.

Third-party disclaimer

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Application number

1830767

Registration number

TMA1056429

Type(s)

Word

Category

Trademark

CIPO Status

REGISTERED

TM5 status

LIVE/REGISTRATION/Issued and Active
The trademark application has been registered with the Office.

Filed

2017-04-03

Registered

2019-09-26

Registration Expiry Date

2029-09-26

Registered Owner

Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
UNITED STATES OF AMERICA

Agent

SMART & BIGGAR LP
Scotia Plaza, 40 King Street West
40th Floor
Toronto
ONTARIO M5H3Y2

Documents

View documents

Index headings

  • CESTRATA
  • CE STRATA

Goods (Nice class & Statement)

5
(1) Pharmaceutical preparations for use in the treatment of cancer, malignant tumours and for suppressing tumors; pharmaceutical preparations for use in the treatment of autoimmune diseases, inflammation, inflammatory diseases and disorders, neurologic diseases and disorders, namely, brain injury, spinal cord injury, seizure disorders, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis and Huntington's disease; pharmaceutical preparations for use in the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; and pharmaceutical preparations for use in the treatment of cardiovascular diseases and disorders.

Claims

  • Proposed Use in CANADA

Action History

Actions
Action Action date Due date Comments
Filed 2017-04-03
Created 2017-04-04
Formalized 2017-04-10
Search Recorded 2017-08-21
Examiner's First Report 2017-08-21 2018-02-21
Correspondence Created 2018-02-23 2018-08-23
Approval Notice Sent 2018-07-13 2018-08-10
Approved 2018-08-30 APPROVED BY PROGRAM EX200M1
Advertised 2018-09-19 Vol.65 Issue 3334
Allowance Notice Sent 2019-01-04 2020-04-03
Allowed 2019-01-04
Registered 2019-09-26 2029-09-26
Agent Changed 2026-04-21 Transferred From: 2502 To: 59
Report a problem on this page
Date modified: